PrognostiX Board Welcomes Dr. Vijay Aggarwal

Life Science Partner recruits industry veteran to board of directors for emerging cardiovascular diagnostics firm

Life Science Partner announces the placement of Vijay Aggarwal, Ph.D., as a member of the board of directors for PrognostiX, Inc. Basing its work largely on research from The Cleveland Clinic, PrognostiX focuses on the role of inflammatory processes in cardiovascular, respiratory, and other disease areas.

“Early-stage companies like PrognostiX can really benefit from the advice and guidance of marketplace veterans,” says Thomas H. Callaway, Life Science Partner’s founder and president. “Vijay is an entrepreneurial CEO with an impressive history at market-leading clinical lab companies. He knows the diagnostic testing business, so we’re pleased that we were able to connect Vijay with PrognostiX’s board.”

Dr. Aggarwal is a seasoned executive who has held senior-level positions in the diagnostic lab sector as well as in pharmaceutical and medical device development. He agreed to join the board based on his assessment of PrognostiX’s core platform of laboratory tests, which show promise in enhancing cardiovascular diagnoses. He is currently CEO and president of Aureon Biosciences, which is developing pathology technologies that predict individual clinical outcomes by analyzing tissue.

Prior to Aureon, Dr. Aggarwal was president at aaiPharma. In addition to leading all research and development activities for this specialty pharmaceutical company, he was responsible for a $100 million contract product development business that served start-up, pharmaceutical, and medical device companies.

With Quest Diagnostics, as president of Quest Diagnostic Ventures, Dr. Aggarwal oversaw e-commerce strategy, pharmaceutical clinical trials, medical diagnostic equipment, medical informatics, point-of-care testing and other high-growth opportunities. He also held P&L responsibility for an existing product portfolio and headed the lab operations integration team during the merger between Quest and SmithKline Beecham Clinical Laboratories (SBCL).

With SBCL for more than a decade, Dr. Aggarwal rose from his position as a regional technical director to vice president and director of U.S. laboratories, with responsibility over $1.2 billion in sales.

Dr. Aggarwal has also consulted in the areas of e-prescribing, pharmacogenomics, healthcare informatics, clinical diagnostics and technology licensing for companies such as WebMD, Genomic Health, InstantDX, and Plexus Ventures.

Dr. Aggarwal holds a doctorate in pharmacology and toxicology from Virginia Commonwealth University, Medical College of Virginia Campus, and a bachelor’s degree in chemistry from Case Western Reserve University.